Methyl 2-aminocyclopentanecarboxylate hydrochloride | 1333850-16-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物的盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl 2-aminocyclopentanecarboxylate hydrochloride
• 英文别名: methyl 2-aminocyclopentane-1-carboxylate;hydrochloride
• CAS: 1333850-16-0；119993-55-4
• 化学式: C7H14ClNO2
• mdl: MFCD16294264
• 分子量: 179.64
• InChiKey: KXQFCNYQRWIKML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.25
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

制备方法与用途

顺式-2-氨基环戊烷甲酸甲酯盐酸盐是一种常见于药物合成的片段，在新药研发过程中广泛使用。已有文献表明，它可以用于制备二酰基甘油酰基转移酶抑制剂。

反应信息

• 作为反应物：
  描述：

  Methyl 2-aminocyclopentanecarboxylate hydrochloride 、 二碳酸二叔丁酯 、 氢化铝锂 、 三氟乙酸 生成 (2-aminocyclopentyl)methanol;2,2,2-trifluoroacetic acid
  参考文献：
  名称：

  OHKI, HIDENORI;INAMOTO, YOSHIKO;KAWABATA, KOHJI;KAMIMURA, TOSHIAKI;SAKANE+, J. ANTIBIOTICS, 44,(1991) N, C. 546-549

  摘要：

  DOI：

文献信息

• Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
  申请人：——

  公开号：US20020016336A1

  公开（公告）日：2002-02-07

  The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR a , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.

  本发明申请描述了新颖的环状β-氨基酸衍生物，其通式为I：1或其药学上可接受的盐形式，其中环B是含有0-2个选自O、N、NRa和S(O)p的杂原子以及0-1个羰基的5-7元环状系统，其他变量在本文中有定义，这些化合物可作为金属蛋白酶和/或TNF-α抑制剂使用。
• [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE<br/>[FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011080718A1

  公开（公告）日：2011-07-07

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。
• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20090093497A1

  公开（公告）日：2009-04-09

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是公式(I)的化合物，以及其药物可接受的盐，其中取代基如规范中所述。这些化合物和含有它们的药物组合物对于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征是有用的。
• INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120289505A1

  公开（公告）日：2012-11-15

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体；以及它们的药学上可接受的盐，药学上可接受的溶剂化合物和药学上可接受的多晶形态。本发明还涉及制造这些杂环化合物的方法以及含有它们的制药组合物。所述化合物及其制药组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，尤其是DGAT1。本发明还提供了一种通过向需要治疗的哺乳动物中给予所述化合物或其制药组合物的治疗方法来治疗这些疾病或紊乱的方法。
• Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
  申请人：——

  公开号：US20040116491A1

  公开（公告）日：2004-06-17

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R 11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式 (I) 的新型海因衍生物： 1 或其药学上可接受的盐或原药形式，其中 A、L 和 R 11 可用作基质金属蛋白酶 (MMP)、TNF-&agr; 转换酶 (TACE)、凝集素酶或其组合的抑制剂。